Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
Pharma News, 2024
FDA grants orphan drug status to HI-Bio’s felzartamab for AMR
Clinical trials demonstrated felzartamab’s potential to improve outcomes in diseases caused by pathogenic antibodies. Felzartamab is being developed to treat antibody-mediated rejection in kidney tr...
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory disease...
Researchers reveal imaging technology could help diagnose and treat bowel cancer
Researchers from the Cancer Research UK (CRUK) Scotland Institute and the University of Glasgow have revealed that imaging technology could be used as a new approach for diagnosing and treatin...
Keytruda combination treatment for NSCLC falls short in Phase III
Despite being a key revenue generator for Merck (MSD), recent months have seen Keytruda (pembrolizumab) navigating a rocky terrain in the non-small cell lung cancer (NSCLC) spa...
Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma
Bristol Myers Squibb (BMS) has announced that Abecma (idecabtagene vicleucel) has been approved by the European Commission (EC) to treat patients with relapsed or refractory mu...
World’s Most Expensive Drug Is Now $4.25 Million
The one-time treatment, Lenmeldy, is used to correct the underlying cause of a hereditary condition called early-onset metachromatic leukodystrophy.
Despite inquiry, FDA AdCom backs BMS Abecma approval
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients. Abecma is a B-cell maturation antigen (BCMA) dir...
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.
Novartis begins expansion of Singapore biopharmaceutical plant
Novartis has broken ground on the expansion of its biopharmaceutical manufacturing facility in Singapore, which aims to meet the increasing demand in the Asian market.
Orchard follows buyout with FDA approval of rare disease gene therapy
The decision makes available in the U.S. a gene therapy GSK first began working on more than a decade ago.
AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell ca...
32
33
34
35
36
37
38
39
40
